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‘Personalised medicine’ aims to tailor interventions to the individual, and has become one of 
the fastest growing areas of cancer research. One of these approaches is to harvest cancer 
cells from patients and grow them in the laboratory, which can then be subjected to 
treatments and the response assessed. We have developed a 3D tumour model with a complex 
protein matrix that mimics the tumour stroma, cell to cell and cell-matrix interactions seen in 
vivo, called a tumouroid. In this study, we test the acceptability and feasibility of using this 
model to establish patient-derived tumouroids. 
 
Methods and analysis:  
This is a first in-human study using prospective tissue and data collection of adult participants 
with confirmed or suspected renal cell carcinoma. The goals of the study are to assess patient 
acceptability to the use of patient-derived tumour models for future treatment decisions, and 
to assess the feasibility of generating patient-specific renal cancer tumouroids that can be 
challenged with drugs. These goals will be realised through the collection of tumour samples 





structured interviews with patients (expected n=5). Collected multiregional tumour samples 
will be dissociated to isolate primary cells which are then expanded in vitro and incorporated 
into tumouroids. Drug challenge will ensue and the response will be categorised into 
“responder”, “weak responder”, and “non-responder”. Statistical analysis will be descriptive. 
 
Ethics and dissemination: The study has ethical approval (REC reference 17/LO/1744). 
Findings will be made available to patients, clinicians, funders, and the National Health 
Service (NHS) through presentations at national and international meetings, peer-reviewed 
publications, social media and patient support groups. 
 
Trial Registration: Registered on ClinicalTrials.gov (NCT03300102). 
 
Keywords:  
Renal cell carcinoma, precision medicine, in vitro techniques, drug screening assays, 
personalised cancer treatment, 3D in vitro cancer models 
 
Strengths and limitations: 
- This is the first study to assess patient acceptability of using patient derived cell 
culture models as a personalised medicine method. 
- This is the first study to formally assess the feasibility of using patient derived kidney 
cancer 3D tumour models. 
- The tumouroid model may not capture the full extent of in vivo tumour heterogeneity.  
- This study will provide feasibility and aims to will inform the design and sample size of 
a clinical trial of comparing personalised tumouroid response to therapy versus 








More than three hundred thousand people are diagnosed with cancer each year in the UK [1], 
resulting in an NHS cancer-related expenditure of £6.7 billion during 2012/3 [2]. These costs 
will rise due to increases in incidence, longevity, and use of novel, more costly treatments.  
For example, per patient costs for immunotherapy (such as Nivolumab [2]) is approximately 
£68000 per annum. In addition, failure of first line treatments requiring second line 
interventions will expend time and money and may lead to disease progression, which is 
costly to treat. 
 
Although the diagnostic and treatment pathways for many cancers continue to improve, 
discrimination between responders and non-responders is less than optimal. There is a need 
to develop tools that allow for better disease characterisation and stratification. The ultimate 
goal is to develop personalised medicine to the level whereby prevention, diagnosis, and 
treatment of disease is tailored to the individual to reduce side effects, improve access to 
effective treatment, and decrease cost [3]. Enhancing the ability to predict response to 
treatment may be more cost-effective than designing new therapeutic options.  
 
The Stratified Medicine Programme [4] represents the most coordinated approach to the 
problem of personalised medicine in the UK. However, to date, only limited success can be 
claimed. The two best examples are HER2 testing (breast cancer) and K-RAS testing (colon 
cancer); the latter results in an increased overall survival of 0.034 years resulting in an 
incremental cost-effectiveness ratio of approximately $650,000 per additional year of life [5], 
which is equivalent to £491,855 far in excess of the NICE threshold of £20-£30K per QALY. 
 
This predictive approach might not be sustainable, as the transition from a morphology-based 
to a genetics-based taxonomy of cancer has considerable challenges. For example, recently a 
number of morphology-agnostic trials have been conducted whereby patient selection is 
solely driven by molecular alterations present within the tumour (basket trials). Reported 
treatment responses have been lower than anticipated [6], possibly due to an over 






An alternative to prediction is verification or authentication. Cancer cells can be harvested 
from patients and grown in animal models, which can then be subjected to treatments and 
response assessed. This information can be used to inform care.  A sample obtained from the 
patient’s tumour is implanted into mice, and allowed to grow; the implanted tumour is then 
tested against an array of clinically relevant agents. However, the process can take over 6 
months to obtain data on tumour responsiveness, and is expensive (US$20,000 per patient) 
[7]. In addition, there are concerns about the ability of animal models to predict behaviour of 
human tumour; this was reinforced by the European Medicine Agency in 2012: ‘the absence of 
[non-clinical models with good predictive properties] is considered to constitute the greatest 
hurdle for efficient drug development within the foreseeable future’ [8]. 
 
Another approach, explored here, involves the use of 3D in vitro tumour models. Cancer cells 
can be harvested from patients and grown in the lab, using a system that provides an extra 
level of complexity to 2D in vitro studies. With these models, it is possible to recreate tumour 
characteristics unavailable in 2D, such as interactions between cancer cells and stromal cells, 
cell-matrix interaction, or hypoxia. The advantages of using 3D tumour models over 
xenografts could be a faster timeline to obtain data on tumour responsiveness, coupled with 
decreased cost and less ethical concerns. This promising new technique needs to undergo 




A 3D complex tumour model – named “tumouroid”- has been developed in our laboratories. 
Our preliminary work used two different kidney cancer cell lines (Caki-2 and 786-O) to 
establish tumouroids and challenge them with therapeutic agents. This work enabled us to 
define ideal growth conditions, the best timings of drug and dose challenge, and how to assess 
drug response. A commercially available protocol was employed with modifications to 
increase the density of the supporting matrix (RAFT, Lonza, UK [9]). Proteins commonly 
found in renal tumours (collagen type I, collagen type IV, laminin and fibronectin) were added 
to mimic the microenvironment as closely as possible to human tumour tissue, by taking into 
account cell to cell and cell-matrix interactions more accurately. We then progressed to 







METHODS AND DESIGN 
 
Study Design 
A first-in-human study using prospective tissue and data collection of participants with 
confirmed or suspected renal cell carcinoma in combination with questionnaires and 
interviews to assess acceptability (Figure 1).  
 
Study aims and outcomes 
The primary objective of this study is to assess patient acceptability for the use of 
personalised lab-based  tumour models for future treatment decision.  
 
The secondary objective is to assess the feasibility of generating patient-specific renal cancer 
tumouroids to be used as platforms to test drug response, including defining the following: 
- Rate of success of establishing kidney cancer tumouroids from fresh tumour tissue, 
defined as number of participants where patient-specific tumouroids were established; 
- The ideal dose(s) of drug to be used when challenging the kidney cancer patient-
derived tumouroids; 
- Number of kidney cancer tumouroids that were successfully therapeutically 
challenged; 
- The expected timeline from tissue collection to therapeutic response assessment in 
kidney cancer patient-derived tumouroids.  
 
Trial population  
Recruitment will be conducted over a period of eight months. Patients with suspected or 
confirmed renal cancer who are undergoing partial or radical nephrectomy, identified during 
the weekly multidisciplinary team meeting or at the time of pre-operative counselling clinics, 
will be approached. Only patients who have agreed to surgery as part of standard of care will 
be approached - no surgery will be carried out for research purposes.  The eligibility criteria 






a) Inclusion Criteria 
 Adult patients (≥18 years old), of either gender, able to provide consent; 
 Suspected or confirmed renal cell carcinoma; 
 Signed informed consent by patient. 
 
b) Exclusion Criteria 
 Non-English speaker; 
 Inability to provide informed consent. 
 
Sample Size 
This pilot study will include 10 participants with confirmed or suspected renal cell carcinoma 
for tissue donation. Ten participants will also complete a Likert scale non-validated 
questionnaire looking at acceptability, and five will complete a semi-structured interview. The 
three groups may overlap. 
 
Screening and enrolment 
A screening log will be maintained of subjects who potentially meet the eligibility criteria 
identified by the clinical research team at multidisciplinary cancer team meetings and at clinic 
appointments.  These subjects will be approached by a member of the clinical research team 
to have an initial conversation about the study, either face to face in clinic, over the telephone 
or by letter.  Subjects who express an interest in participation will then be given a copy of the 
REC approved patient information sheet (PIS) and given time to consider the study.  
 
Those who confirm willingness to participate will be approached to give informed consent. 
The subject must be given ample time (without breaching the NHS cancer waiting/treatment 
times) and opportunity to inquire and ask questions about the trial and to decide whether or 
not to participate. The right of the subject to refuse to participate in the trial, with or without 
giving a reason, must be respected. 
 
Subjects who are screened but are then deemed ineligible, or those who choose not to 







Participants who sign the study consent form are deemed to be recruited into the study and 
will then be assigned a unique subject number. The original signed consent form will be filed 
in the investigator's site file, a copy given to the participant and a copy filed in the hospital 
case notes.  
 
Interventions & Outcomes 
Tissue Collection 
The surgical specimen removed at nephrectomy will be delivered fresh (i.e. without any tissue 
preservatives such as formalin) from theatre to the Pathology Department at Royal Free 
Hospital.  After assessment by a trained pathologist to ensure diagnosis is not compromised, 
samples of tumour and of adjacent normal kidney tissue will be extracted using a blade or a 
biopsy punch. These tissue samples will be delivered to the designated laboratory of the UCL 
Division of Surgery & Interventional Science located at Royal Free Hospital where they will be 
mechanically and chemically digested to generate a suspension of single cells, then 
transferred to common tissue culture plates to allow for cell proliferation. After up to 8 weeks 
of expansion, patient-specific tumouroids will be established and maintained. If cell expansion 
is deemed unsuccessful at 8 weeks, the experiment will be terminated without 
mamufacturing patient-specific tumouroids. At day 10 after tumouroid establishment, drug 
challenge with pazopanib will be carried out, followed by assessment of drug response at 72h 
using a commercially available assay - Cell-Titer Glo 3D (Promega, USA) - that determines cell 
metabolism and viability. Immunofluorescent imaging will also be used to assess cell 
morphology As this platform and the results of its drug challenge are experimental and have 
not been clinically validated, individual patient level results will not be disclosed to 
participants or the clinical team. 
 
If participants have also consented to donate tissue samples of tumour and adjacent normal 
kidney to be used in other current or future ethically approved studies, one or more of these 
samples may be cryopreserved, and stored at the UCL/Royal Free Hospital biobank facility.  
 
All procedures will follow steps described in a number of laboratory standard operating 






Each phase of the tissue model production (tumouroid establishment, therapeutic challenge, 
and assessment of drug response) will be scored as completed, partially completed or 
incomplete. Tumouroids that achieve viability and are subjected to in vitro therapeutic 
challenge will be scored as responder” (typically 50% cell death after drug challenge), “weak 
responder” (around 25% cell death after drug challenge), and “non-responder” (typically 0% 
but with an upper threshold of 10% cell death after drug challenge). These ranges were 
established using renal cancer cell line tumouroids, treated with pazopanib, using a range of 
different pharmacological protocols (unpublished data).  
Given the diversity of cells present within tumours, assurance is required to confirm that 
isolated and proliferating cells are malignant. As such, after cell expansion (and prior to 
tumouroid establishment), DNA and/or RNA will be extracted for genetic analysis. Stored 
tissue will undergo the same process for comparison with the grown cells, as appropriate. The 
purpose of genetically testing cells before tumouroid establishment is solely to confirm that in 
vitro expanded cells harbour renal cancer-related mutations and thus are not expanded 
benign/interstitial cells. Genetic analysis will not guide the tumouroid drug challenge. The 
results obtained from this genetic testing may not fully represent the true genetic landscape 
of the tumour as it was in vivo prior to nephrectomy. This will be due, in part, to 
intratumoural heterogeneity [10] and because the cancer cells will have already been grown 
in the laboratory (thus exposed to ex vivo selective pressures that may have contributed to 
changing the genetic landscape of the proliferated cells). For the above reasons, patients and 
the clinical team will not be informed of any genetic testing results. 
 
Questionnaire 
Acceptability will be elicited using a Likert scale non-validated questionnaire. Questionnaire 
responses will be coded prior to descriptive analysis. 
 
Interview 
A subgroup of participants will be invited to a semi-structured interview in which the views 
and preferences relating to the acceptability of the laboratory-based personalised tumour 
models and their impact on future decision making will be explored. The interview could take 
place over the telephone, or face to face in a quiet clinic room, either before or after a clinic 





will be pseudo-anonymised, the first transcripts from the semi-structured interviews will be 
analysed and coded by two independent researchers for themes and patterns.  
 
Participant withdrawal 
Participants may be withdrawn from the study for the following reasons: 
 Participant choice; 
 Pathology analysis after harvesting proving histologic diagnosis other than renal cell 
carcinoma; 
 Inability to collect sample due to risk of compromising pathologic staging during tissue 
collection. 
 
Patient and public involvement 
Patients and members of the public (including those who have had cancer) have been 
involved in the design of the study, and will participate in the management of the research, 
and analysis and dissemination of the findings.  
 
Data collection  
Baseline clinical data and demographics will be collected. After tissue collection, the 
pathology report and staging will be obtained. Responsibility for data collection will be taken 
by nominated individuals. Data will be collected using an electronic case report form (eCRF). 
Data will be stored centrally by the Surgical & Interventional Trials Unit (SITU) at UCL.  
 
Data will be held according to the Data Protection Act, 2018 and General Data Protection 
Regulation (GDPR). Data will be pseudo-anonymised as necessary. The key to the pseudo-
anonymised data will be held at site, on a secure NHS computer or if a paper file is preferred it 
will be kept in a fire-proof lockable cabinet.  Each participant will be given a subject number 
and subject identifier and this will be used on all of their study records.  The subject number 
and subject identifier will be known to site staff and the SITU team.  All clinical information 
required will be kept in study records and analysed at the end of the study. The records will 
be kept in a secure manner in the research offices with access available to named individuals 
from the study group only. The paper records will be retained for a minimum of three years 







a) Demographics and clinical information 
 Age; 
 Gender; 
 If previous diagnosis of renal cancer: date of diagnosis, staging at time of diagnosis 
(TNM), any previous local treatment (type and date); 
 Family history of first degree relatives with same cancer type and/or presence of 
previous diagnosis of hereditary syndrome associated with malignancies; 
 Current clinical staging (TNM); 
 Pathology report and staging. 
 
b) Feasibility-related information: 
 Number of tumour tissue samples collected; 
 If adjacent normal tissue also collected, number of tissue samples; 
 Gross morphology, weight and size of each sample; 
 Date and time of tissue collection; 
 Date and time of arrival to laboratory; 
 Date and time of tissue processing; 
 Method of cell isolation; 
 Cell count after isolation; 
 Cell growth method and time; 
 Characterisation of cells; 
 Date of tumouroid establishment; 
 Date of drug challenge; 
 Drug concentrations tested; 
 Duration of drug exposure; 
 Drug challenge response. 
 
c) Acceptability-related information: 
 Questionnaire responses (coded); 
 Semi-structured interview responses (coded). 
 





Analyses will be descriptive; continuous variables will be summarised using the mean, standard 
deviation, median, and interquartile range; categorical variables will be summarised as 
frequencies and proportions; all estimates will include confidence intervals. 
 
Trial Funding, Organisation and Administration 
The study funding has been reviewed by the sponsor and deemed sufficient to cover the 
requirements of the study. NHS costs will be supported via Royal Free London NHS 
Foundation Trust.  
 
The research costs for the study are supported by National Institute of Health Research i4i 
Invention for innovation grant (reference number: II-LA-0813-20002; funding amount: 
£1,170,986.00; date of award: 1st July 2014). 
 
Ethics and dissemination 
The study has ethical approval from the London Central Research Ethics Committee (REC 
reference 17/LO/1744). The results of the study will be published in peer-reviewed 
publications and will be presented at relevant national and international conferences. We will 
work with our patient panel to develop plain English reports to disseminate research findings 
to patient groups and the clinical teams at participating sites. 
 
Availability of data 
The Surgical & Interventional Trials Unit (SITU) will control the final trial dataset and any 
requests for access must adhere to the current SITU data sharing policy, subject to existing 
contractual arrangements with the funders. The protocol, sample case report forms and 
participant information are available on upon request to the corresponding author. 
 
Trial Status 
The trial opened to recruitment on 10 January 2018. Amendments were reviewed and 
approved by the sponsor, and the National Research Ethics Service Committee. Protocol 








Personalised medicine has the potential to improve health outcomes in the NHS and globally. 
It is estimated that half the UK population will receive a cancer diagnosis within their lifetime 
[11]. Treatments are improving, but they are also becoming more expensive, particularly in 
relation to new drugs. However, tools to discriminate between responders from non-
responders are limited and so all patients will be offered a trial of therapy. It is only by giving 
treatments that are destined to work that we can maximise cost-effectiveness and minimise 
harm. 
 
If proven acceptable to patients and feasible, in vitro-directed therapy could be a very useful 
personalised approach to guide treatment decisions. The development of patient-derived 
tumouroids could overcome the current over-simplified strategies that focus on gene or 
protein markers as predictors of response, and ignore epigenetic and functional alterations 
within cancer cells and the influence of tumour stroma on treatment sensitivity. Limitations to 
this approach could still be not capturing the full extent of intratumoural heterogeneity and 
inducing in vitro selective pressures that are not present in vivo and could alter treatment 
response. The use of multiregional tumour sampling and short culture timeframes are two 
strategies used to limit these potential shortfalls. In addition, patient-derived tumouroids 
could be used as a standalone platform or as a verification tool coupled with other 
personalised medicine approaches. 
 
Subject to successful testing, establishing tumouroids as a personalised platform to predict 
patient response to treatment could represent a more cost-efficient and ethical tool than 
animal platforms. This proof-of-concept study will assess if patient-derived tumouroids can 
be therapeutically challenged in a clinically relevant timeframe, and if patients are willing to 
accept such a method to guide clinical treatment decision making. The results will be used to 
inform the sample size, design and conduct of a subsequent early phase development 
programme comparing personalised tumouroid response to therapy versus patient response 
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Table 1: Study assessments within the tumouroids study 
Visit Before surgery/Baseline Surgery After surgery/Exit 
Screening X   
Informed consent X   
Demographic data, medical 
history, other clinical history 
X   
Tissue collection  X  
Tumouroid establishment and drug 
challenge 
  X 
Pathology assessment confirming 
the diagnosis of kidney cancer 
  X 
 
 
Participants who consent to complete either the structured questionnaire and/or to be 








- First study on patient acceptability of patient derived cell culture models. 
-First study to assess the feasibility of using patient derived kidney cancer 3D tumour models. 
-Study will inform the design of a clinical trial in personalised tumouroid response to therapy. 
 
 
